Skip to main content

Table 3 Summary of results per hundred infants from the base case model

From: A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

  Palivizumab No prophylaxis  
  Costs QALYs Costs QALYs ICER
CHD infants £636,108 2,597 £449,120 2,591 £33,216
CLD infants £569,491 2,613 £440,816 2,606 £19,168
Preterm infants      
<29 wGA £367,776 2,622.94 £354,226 2,619.42 £3,845
29-32 wGA £353,668 2,623.12 £272,481 2,620.43 £30,205
33-35 wGA £318,079 2,622.90 £73,621 2,620.43 £99,056
  1. Abbreviations: CHD Congenital heart disease, CLD Chronic lung disease, wGA weeks of gestational age, QALY Quality-adjusted life-year, ICER Incremental cost-effectiveness ratio.